Multiple Myeloma Coverage From Every Angle

Published Medical Literature

Frailty Index May Predict Survival in Newly Diagnosed Myeloma
Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma
Novel Signaling Pathway: Route to Potential Therapy for Multiple Myeloma?
Access to Care: Thalidomide-Based Therapy in Multiple Myeloma
ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma
Analysis of Bone Marrow Stromal Cells in Patients With Myeloma During Chemotherapy
Survival Benefits of Maintenance Therapies for Multiple Myeloma
Guidelines for Managing Clostridium Difficile Infection in Younger Transplant Recipients
End-of-Life Care After Allogeneic Hematopoietic Cell Transplantation
Investigating Link Between Cancer-Related Fatigue and Survival in Myeloma
Multiple Myeloma and Bone Metastases: Dosing Interval of Bone-Modifying Agents
Combination Therapy for Older Transplant-Ineligible Patients With Multiple Myeloma
Predictive Risk Factors for Outcome After Transplantation for Myeloma
Destabilizing NEK2 May Overcome Resistance to Treatment in Multiple Myeloma
Update on Reduced-Intensity Conditioning for Certain Hematologic Malignancies
Immunotherapy in Multiple Myeloma: Today and Tomorrow
Twice-Weekly Ixazomib May Benefit Some Patients With Newly Diagnosed Multiple Myeloma
Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma
Long-Term Outcomes Reported With Escalated Melphalan in Multiple Myeloma
Time to Myeloma Diagnosis: Room for Improvement
Is Stem Cell Transplant Still Relevant in Today’s Treatment of Multiple Myeloma?
Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma
Carfilzomib in Resistant Myeloma: Once Weekly Versus Twice Weekly
Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?
Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma
PANORAMA-1 Trial in Multiple Myeloma: Patient-Reported Outcomes With Panobinostat
Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma
New Research Finds Clues to Reducing Bortezomib-Linked Neuropathy
Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma
How Closely Do Circulating Tumor Cells, Cell-Free DNA, and Bone Marrow Biopsies Agree?
Is Higher Body Mass Index a Risk Factor for Multiple Myeloma?
Potential of Folate-Targeted Therapies for Multiple Myeloma
Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma
Is DCEP Chemotherapy a Viable Bridge to Definitive Therapy in Resistant Myeloma?
Screening Strategies in Individuals at Risk of Developing Multiple Myeloma
Are Recipients of Hematopoietic Cell Transplantation at Risk for Cognitive Decline?
Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease
Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma
High-Dose Therapy Followed by Autologous Stem Cell Transplant for Multiple Myeloma
Considering Newer Agents in Managing Relapse in Resistant Myeloma
BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma
Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma
Infection Prevention in Patients With Multiple Myeloma
Early Research Studies May Advance the Treatment of Multiple Myeloma
Carfilzomib and Cardiovascular Adverse Events in Patients With Multiple Myeloma
Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells
Survival and CRP Levels Prior to Transplantation in Patients With Multiple Myeloma
Novel Three-Part Treatment Sequence in High-Risk Multiple Myeloma
What Role, If Any, Does Obesity Play in MGUS and Multiple Myeloma?
Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma
Differences in Genetic Mutations in Blacks and Whites With Multiple Myeloma
Venetoclax Combination Therapy for Relapsed or Refractory Multiple Myeloma
Can Type of Myeloma Influence Response to Monoclonal Antibodies?
Multiple Myeloma Precancerous Disease and African Americans
Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma
Protein Kinases CK1-alpha and CK2 in Pathogenesis of Multiple Myeloma
Carfilzomib Versus Bortezomib in Relapsed or Refractory Multiple Myeloma
Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma
Lenalidomide Maintenance After Transplantation in Multiple Myeloma
MRI Versus PET-CT in Symptomatic Patients With Multiple Myeloma
Bendamustine, Prednisone, and Bortezomib Treatment for Light Chain Multiple Myeloma
Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma
Treatment Tolerability in Patients With Relapsed or Refractory Multiple Myeloma
Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Induction and Maintenance Therapies With Bortezomib in Myeloma
Prognostic Impact of MRD-Negative Status in Multiple Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study
Combination Treatment With or Without Transplantation in Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.